• MLN2238: Practical Proteasome β5 Workflows

  2026-10-01

  MLN2238 enables controlled chymotrypsin-like proteasome inhibition for apoptosis, proteostasis, and resistance studies. This guide connects target engagement with ROS/JNK/CREB signaling while providing practical dosing, solubility, washout, and troubleshooting strategies.

• ZCL278: An Assay-First Guide to Cdc42 Biology

  2026-09-30

  ZCL278 is a selective Cdc42 inhibitor for connecting biochemical target engagement with changes in cell motility, neuronal development, and signaling. This assay-first guide interprets ZCL278 alongside a kidney fibrosis study to clarify what the compound can reveal, which controls matter, and where evidence remains preliminary.

• Pexmetinib (ARRY-614) Cytokine Assay Workflow

  2026-09-29

  Build more informative inflammation assays with Pexmetinib (ARRY-614), a dual p38 MAPK and Tie2/Tek inhibitor suited to cytokine, phospho-signaling, and bone-marrow microenvironment studies. This workflow connects dose-response design, orthogonal readouts, and troubleshooting for inflammatory cytokine inhibition and myelodysplastic syndromes research.

• How p38α Inhibitors Control Dephosphorylation

  2026-09-29

  The reference preprint identifies a dual-action mechanism in which selected kinase inhibitors both block p38α activity and accelerate WIP1-mediated removal of the activation-loop phosphate. Structural and biochemical evidence shows that inhibitor-stabilized activation-loop conformations expose the phospho-threonine, suggesting a strategy for improving kinase-inhibitor potency and signaling specificity.

• Co-IP Strategy for PINK1 SUMOylation in Parkinson’s

  2026-09-28

  A translational framework for using co-immunoprecipitation to interrogate the UBC9–PINK1 axis, with practical guidance on controls, magnetic-bead workflows, and the limits of moving from preclinical association to therapeutic insight.

• Fluo-4 AM in Diabetic Kidney Calcium Signaling

  2026-09-28

  Fluo-4 AM can help researchers resolve calcium dynamics downstream of AT1R in podocytes, where receptor trafficking may influence diabetic kidney injury. This article connects calcium-indicator choice to the mechanistic findings of a 2025 GPR107 study and explains what fluorescence can—and cannot—establish.

• Podophyllotoxin Workflows for Cancer Research

  2026-09-27

  Use Podophyllotoxin as a microtubule-directed benchmark to connect mitotic disruption with cell-cycle, viability, and apoptosis readouts. A recent hepatocellular carcinoma study offers a useful autophagy comparison—but its diterpene findings should guide assay design, not be attributed to Podophyllotoxin.

• SC 79: Practical Akt Activation Workflows

  2026-09-26

  Use SC 79 as a chemical gain-of-function tool to probe Akt-dependent survival signaling, including neuroprotection in ischemic stroke models. This guide pairs a staged cell-based workflow with practical controls, troubleshooting, and a careful comparison to research on SIRT7-mediated suppression of AKT/mTOR signaling.

• Protein A/G Magnetic Co-IP/IP Kit for Assay Follow-Up

  2026-09-25

  Learn when co-immunoprecipitation can add mechanistic context to cell viability and cytotoxicity results, and how to plan controls, optimize recovery, and interpret interaction data. This scenario-based guide explains the documented components and handling considerations of the Protein A/G Magnetic Co-IP/IP Kit (SKU K1309), while distinguishing product specifications from experimental recommendations.

• Linoleic Acid (C18:2): Practical Assay Guide

  2026-09-25

  Linoleic Acid (SKU C3108) provides a defined omega-6 fatty acid reagent for investigating membrane behavior, oxidative stress, erythrocyte injury, and epithelial migration. Use it with vehicle-matched controls and assay-specific pilot testing; it is not, by itself, a standardized dose-validated disease model or proof of a single redox mechanism.

• Mitochondrial Calcium Signaling Represses Ferroptosis

  2026-09-24

  The cited study links mitochondrial calcium uptake through MCU to acetyl-CoA-dependent GPX4 regulation, identifying a metabolic route that helps repress ferroptotic cell death. Its findings connect mitochondrial signaling with ferroptosis susceptibility in mice and cancer models, while highlighting experiments needed to test how broadly the mechanism applies.

• AZ505: Selective SMYD2 Inhibition and Evidence

  2026-09-24

  AZ505 is a substrate-competitive SMYD2 inhibitor for epigenetic regulation research, with product-reported biochemical potency and selectivity. A peer-reviewed cisplatin-induced kidney injury study supports investigating SMYD2 inhibition in renal fibrosis models, but does not establish clinical benefit or efficacy in cancer.

• Bortezomib (PS-341) for UCK2 Turnover Studies

  2026-09-24

  Use Bortezomib (PS-341) as a short-term mechanistic probe to test whether mTORC1-linked UCK2 loss depends on proteasomal degradation—not as a stand-alone explanation of pyrimidine metabolism. A paired workflow combining protein, pathway, and cell-state readouts helps separate UCK2 turnover from general proteotoxicity or apoptosis.

• Nuclear PI3P Links Vps34 to DNA Mismatch Repair

  2026-09-23

  The reference study identifies nuclear phosphatidylinositol-3-phosphate (PI3P), generated by a Beclin-1/Vps34 complex, as a lipid regulator of DNA mismatch repair. Its findings connect Vps34 activity to MutS complex assembly, DNA substrate engagement, microsatellite stability, and damage responses through an autophagy-independent mechanism.

• JNK-IN-7 for JNK-Driven Apoptosis Assays

  2026-09-22

  JNK-IN-7 is a selective JNK inhibitor for resolving c-Jun phosphorylation, inflammatory signaling, and apoptosis in cell-based models. This practical guide connects its covalent kinase mechanism with Candida krusei challenge assays, innate immune signaling modulation, and troubleshooting strategies that separate pathway-specific effects from high-dose off-target activity.

556 records 3/38 page Previous Next 12345 下5页 Last page